nox2

APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.

ML-090 is NOX1-specific inhibitor(IC50 = 90 nM) which is >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50s >10 μM).

4',6,7-Trimethoxyisoflavone promotes wound healing through NOX2 induction, which leads to collective migration and MMP activation.

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury.

Phox-I2 is an NOX2-specific inhibitor. Phox-I2 reverts ROS-accumulation and leads to refusion of mitochondrial networks.

gp91 ds-tat is a NADPH oxidase (NOX2) inhibitor that reduces NOX2 expression.

NOX2-IN-2 diTFA (compound 33) is an effective inhibitor of NOX2, targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. This compound effectively suppresses the production of ROS generated by NOX2 in cells.

NOX2-IN-2 (compound 33) is a potent inhibitor of NOX2, disrupting the p47phox-p22phox protein-protein interaction with a dissociation constant (Ki) of 0.24 μM, and effectively suppressing reactive oxygen species (ROS) production from NOX2 in cellular contexts [1].

NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2), disrupting the p47phox-p22phox protein-protein interaction with high binding affinities and potent activity in cellular assays [1].

NOX2-IN-3 (compound 3), functioning as an inhibitor of NOX2 (NADPH Oxidase 2), enhances the sensitivity of tumor cells to MRTX1133 [1].

CPP11G (Compound 11g) is a highly selective inhibitor of NADPH oxidase 2 (Nox2) with an IC50 of 20 μM. It shows potential for research into inflammatory diseases such as vasculitis and atherosclerosis, as well as conditions associated with excessive Nox2 activation, including ischemia-reperfusion injury.

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.

Seltorexant hydrochloride is a selective, orally active and high-affinity antagonist of OX2R with pKi values of 8.0 and 8.1 for human and rat OX2R.

Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain. Seltorexant is a high-affinity and selective orexin-2 receptor antagonist (pKi: 8.0 and 8.1 for human and rat OX2R).

GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays).

MC4762 is an inhibitor of NOX2 and MAOB, with IC50 values of 0.155 μM and 0.182 μM, respectively. It exhibits anti-inflammatory properties by suppressing the production of ROS and downregulating the expression of pro-inflammatory cytokines such as iNOS, IL-1β, and IL-6.

Phox-I1 is a NOX2 inhibitor targeting the interactive site of p67phox with Rac GTPase.

(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol, a selective β1-adrenergic receptor antagonist (IC50 = 0.8 nM). Nebivolol exhibits vasodilatory activity and can prevent Nox2/NADPH oxidase up-regulation and lipoperoxidation in early stages of ethanol-induced cardiac toxicity.

NoxA1ds TFA is a potent and selective inhibitor of NADPH oxidase 1 (NOX1) with an inhibition concentration (IC50) of 20 nM, showing selectivity over NOX2, NOX4, NOX5, and xanthine oxidase. It effectively inhibits NOX1-derived O2- production in HT-29 human colon cancer cells and attenuates VEGF-induced migration of human pulmonary artery endothelial cells under hypoxic conditions in vitro.

Potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 = 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary

NoxA1ds acetate is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 : 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.